Prospective trials of 2nd and 3rd generation TKI as front-line therapy for Ph+ ALL
| TKI . | Reference . | N . | Age . | Treatment . | CR rate (%) . | Molecular response (%) . | Allogeneic SCT rate (%) . | RFS/EFS (%) . | Survival (%) . |
|---|---|---|---|---|---|---|---|---|---|
| Dasatinib | |||||||||
| 70 mg BID | Foa et al, 2011130 | 53 | 54 (24-77) | Prednisone | 15 (d 85) | 42 | 22 (20 mo) | 31 (20 mo) | |
| 50 mg BID/100 mg QD 100 mg QD-70 mg QD | Ravandi et al, 2015134 | 72 | 55 (21-80) | Hyper-CVAD | 96 | 65 | 17 | 44 (5 y) | 46 (5 y) |
| 50 mg BID/100 mg QD 70 mg QD | Ravandi et al, 2016129 | 97 | 44 (20-60) | Hyper-CVAD | 88 | — | 42 | 62 (3 y) | 69 (3 y) |
| 140 mg QD; >70 y: 100 mg QD | Rousselot et al, 2016135 | 71 | 69 (55-83) | EWALL backbone | 24 | 10 | 28 (5 y) | 36 (5 y) | |
| 140 mg QD | Foà et al, 2020142 | 63 | 54 (24-82) | Corticosteroids | 98 | 60 (2 cycles of blinatumomab | 38 | 88 (18 mo med. FU) | 95 (18 mo med. FU) |
| Nilotinib | |||||||||
| 400 mg BID | Kim et al, 2015143 | 90 | 47 (17-71) | Intensive chemotherapy | 91 | 77 (3 mo) | 63 | 72 (2 y) | 72 (2 y) |
| 400 mg BID | Ottmann et al, 2018144 | 72 | 66 (55-85) | EWALL backbone | 94 | 58 <0.01 | 33 | 42 (4 y) | 47 (4 y) |
| Ponatinib | |||||||||
| 45-30-15 mg QD | Jabbour et al, 2018127 | 76 | 47 (39-61) | Hyper-CVAD | 98 | 83 | 20 | 67 (5 y) | 71 (5 y) |
| 30-15 mg QD | Ribera et al 2022141 | 30 | 49 (19-59) | Intensive chemotherapy alone | 100 | 71 at week 16 | 87 | 70 (3 y) | 96 (3 y) |
| 45-30-15 QD | Martinelli et al, 2022145 | 44 | 66.5 | 90.9 at week 6, 86.4 at month 6 | 47.7 at week 6 40.9 at month 6 | 11 (transplant unplanned) | 48 (3 y) | 58 (3 y) |
| TKI . | Reference . | N . | Age . | Treatment . | CR rate (%) . | Molecular response (%) . | Allogeneic SCT rate (%) . | RFS/EFS (%) . | Survival (%) . |
|---|---|---|---|---|---|---|---|---|---|
| Dasatinib | |||||||||
| 70 mg BID | Foa et al, 2011130 | 53 | 54 (24-77) | Prednisone | 15 (d 85) | 42 | 22 (20 mo) | 31 (20 mo) | |
| 50 mg BID/100 mg QD 100 mg QD-70 mg QD | Ravandi et al, 2015134 | 72 | 55 (21-80) | Hyper-CVAD | 96 | 65 | 17 | 44 (5 y) | 46 (5 y) |
| 50 mg BID/100 mg QD 70 mg QD | Ravandi et al, 2016129 | 97 | 44 (20-60) | Hyper-CVAD | 88 | — | 42 | 62 (3 y) | 69 (3 y) |
| 140 mg QD; >70 y: 100 mg QD | Rousselot et al, 2016135 | 71 | 69 (55-83) | EWALL backbone | 24 | 10 | 28 (5 y) | 36 (5 y) | |
| 140 mg QD | Foà et al, 2020142 | 63 | 54 (24-82) | Corticosteroids | 98 | 60 (2 cycles of blinatumomab | 38 | 88 (18 mo med. FU) | 95 (18 mo med. FU) |
| Nilotinib | |||||||||
| 400 mg BID | Kim et al, 2015143 | 90 | 47 (17-71) | Intensive chemotherapy | 91 | 77 (3 mo) | 63 | 72 (2 y) | 72 (2 y) |
| 400 mg BID | Ottmann et al, 2018144 | 72 | 66 (55-85) | EWALL backbone | 94 | 58 <0.01 | 33 | 42 (4 y) | 47 (4 y) |
| Ponatinib | |||||||||
| 45-30-15 mg QD | Jabbour et al, 2018127 | 76 | 47 (39-61) | Hyper-CVAD | 98 | 83 | 20 | 67 (5 y) | 71 (5 y) |
| 30-15 mg QD | Ribera et al 2022141 | 30 | 49 (19-59) | Intensive chemotherapy alone | 100 | 71 at week 16 | 87 | 70 (3 y) | 96 (3 y) |
| 45-30-15 QD | Martinelli et al, 2022145 | 44 | 66.5 | 90.9 at week 6, 86.4 at month 6 | 47.7 at week 6 40.9 at month 6 | 11 (transplant unplanned) | 48 (3 y) | 58 (3 y) |
BID, twice a day; FU, follow-up; med., median; QD, once a day.